98. Eur J Med Chem. 2018 Mar 25;148:306-313. doi: 10.1016/j.ejmech.2018.02.030. Epub 2018 Feb 12.Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents withdual targeting of microtubules and DNA.Borie C(1), Mondal S(2), Arif T(1), Briand M(1), Lingua H(1), Dumur F(1), Gigmes D(1), Stocker P(1), Barbarat B(3), Robert V(4), Nicoletti C(4), Olive D(3),Maresca M(5), Nechab M(6).Author information: (1)Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire UMR 7273, F-13390Marseille, France.(2)Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire UMR 7273, F-13390Marseille, France; Department of Chemistry, Syamsundar College, Shyamsundar713424, West Bengal, India.(3)Centre de Recherche en Cancérologie de Marseille (CRCM) UMR-INSERM1068-IBiSACancer Immunomonitoring Platform, Inserm, U1068, France; Institut PaoliCalmettes, 27, Boulevard Lei Roure, BP30059, 13273, Marseille Cedex 09, France.(4)Aix Marseille Univ, CNRS, Centrale Marseille, iSm2 UMR 7313, F-13397,Marseille, France.(5)Aix Marseille Univ, CNRS, Centrale Marseille, iSm2 UMR 7313, F-13397,Marseille, France. Electronic address: m.maresca@univ-amu.fr.(6)Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire UMR 7273, F-13390Marseille, France. Electronic address: malek.nechab@univ-amu.fr.A novel series of enediynes possessing pentafluorophenylsulfoxide have beendeveloped. The innovative compounds possess antiproliferative activity against a broad panel of human cancer cells originating from breast, blood, lung, kidney,colon, prostate, pancreas or skin with IC50 ranging from 0.6 to 3.4 μM. Theantiproliferative activity of enediynes in darkness is associated to theirability to compromise microtubule network. In addition, exposure to UV leads todouble-stranded DNA cleavage caused by the newly synthesized molecules reducingfurther their IC50 in nanomolar range against human tumor cells, includingchemo-resistant pancreatic cancer cells. Taken together, the examined datademonstrate that enediynes possessing pentafluorosulfoxide are promisingmolecules in the cancer therapy.Copyright © 2018 Elsevier Masson SAS. All rights reserved.DOI: 10.1016/j.ejmech.2018.02.030 PMID: 29471119  [Indexed for MEDLINE]